Press Release February 24, 2022

SV Health, Jeito and Samsara BioCapital lead $65 million Series A Financing of EyeBio

The London and Cambridge Life Sciences team advised SV Health, Jeito and Samsara BioCapital on their lead $65 million Series A Financing of EyeBio.

EyeBio is seeking to build a platform to find, develop and market blockbuster ocular therapies by in-licensing retinal assets for urgent unmet medical needs with large markets.

SV Health is a Boston based middle-market private equity investment firm specializing in healthcare investments, with expertise spanning biotechnology, dementia, healthcare growth, medical technology and public equities.

Jeito Capital is an independent private equity firm dedicated to biotech and biopharma with a patient benefit driven approach that focuses both on financing ground-breaking medical innovation and promoting positive societal impact.

Samsara BioCapital is a venture capital firm headquartered in Palo Alto, California founded in 2016. The firm seeks to invest in the life sciences, oncology and digital healthcare sectors with the goal to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance.

The deal team consisted of Graham Defries, Tim Worden, Lucy Sharples, Luke Nauth, Matthew Connell and Kenny Walker-Durrant.